1. Introduction {#sec1-ijms-17-00960}
===============

Tuberculosis (TB) is one of the leading causes of death worldwide \[[@B1-ijms-17-00960]\]. Global international migration flows, Human Immunodeficiency Virus (HIV)-related immunodeficiency, immunosuppressive therapies and the spread of multidrug-resistant (MDR) strains have been recognized as the most important factors leading to an increased TB incidence \[[@B2-ijms-17-00960]\]. Epidemiologic data on childhood TB are still limited. In 2013, the WHO estimated nine million (range 8.6--9.4 million) new TB cases/year, equivalent to 126 cases per 100,000 populations, with about 6% of those cases occurring in children \[[@B1-ijms-17-00960]\]. The estimation methods presently have some limitations including misdiagnosis due to difficulties in childhood TB diagnosis, under-reporting and unavailability of age-disaggregated data. In 2013 the total number of new and relapsed cases among children was 275,000 in countries that reported age-disaggregated notification data for 2013 \[[@B1-ijms-17-00960]\]. In Europe, 2625 TB cases in children below age 15 were reported in 2013, accounting for 4% of all notified TB cases \[[@B3-ijms-17-00960]\]. Romania, Spain and the United Kingdom accounted for more than half of the cases. In 2013, the total number of active TB-notified cases in Italian children (0--14 years) was 124, corresponding to 4.7% of the European cases in the same year \[[@B3-ijms-17-00960]\].

Childhood TB is considered as a sentinel of disease spreading throughout the community \[[@B2-ijms-17-00960]\]. Furthermore, children are particularly vulnerable to severe disease and death following a TB infection, and those with a latent infection could become a reservoir of disease reactivation in adulthood \[[@B2-ijms-17-00960]\]. As a result, pediatric TB deserves prompt identification. Although local databases have been implemented in single institutions \[[@B4-ijms-17-00960],[@B5-ijms-17-00960],[@B6-ijms-17-00960],[@B7-ijms-17-00960]\], this is the first Italian nationwide Register on Pediatric Tuberculosis.

2. Results {#sec2-ijms-17-00960}
==========

Children with active TB, latent TB, and those recently exposed to TB or recently adopted/immigrated from a high TB incidence country. Overall, 4234 children were included from 27 centers. According to the infection status, 554 (13.1%) children had active TB, 594 (14.0%) latent TB and 3086 (72.9%) were uninfected. The anagraphic data and the main characteristics of the children enrolled are reported in [Table 1](#ijms-17-00960-t001){ref-type="table"}.

Overall, 21.6% of the patients enrolled were Italian. Children of foreign origins were more frequently from Asia, Eastern Europe and South America, and the same distribution was found in all groups.

Overall, a BCG (Bacillus Calmette--Guerin) vaccination status was reported only in 74% of children.

2.1. Uninfected Children {#sec2dot1-ijms-17-00960}
------------------------

Considering the 3086 uninfected children, 2782 (90.1%) had a response to TST ≤ 5 mm, whereas 304 had a TST \> 5 mm (9.9%). Among these, 294/304 (96.7%) had a negative IGRA test; the IGRA result was unknown in seven (1.8%) and indeterminate in three (0.8%) children. One hundred sixty-one children were screened for TB because of symptoms/signs. The most common clinical features were lymphadenopathy in 45 (27.9%) cases and fever in 15 (9.3%) cases. The median age of these children was 68 (IQR: 38.5--123) months.

2.2. Children with Tuberculosis (TB) {#sec2dot2-ijms-17-00960}
------------------------------------

The main characteristics of children with TB are reported in [Table 1](#ijms-17-00960-t001){ref-type="table"}. As shown, children with active TB were significantly younger compared to those with latent TB (*p* \< 0.001). Moreover, active TB patients were often investigated because they were symptomatic or recently exposed to a TB case (521/553, 94.2%), whereas children with latent TB were mainly investigated for screening purposes (359/594, 60.4%). A significantly higher proportion of Italian children were affected by active compared to latent TB (27.4% *vs.* 11.8%; 95% CI: 10.9--20.2; *p* \< 0.0001).

Among 541 children with active TB for whom both birthplace and country of origin were known (of the child if born abroad or of the parents), 141 (26.8%) were born in Italy from Italian parents, 240 (44.4%) were born in Italy from foreign parents and 156 (28.8%) were born abroad from foreign parents.

A significantly higher proportion of children with latent TB were vaccinated with BCG compared to active TB cases (49.2% *vs.* 11.3%; 95% CI: 32.8--42.7; *p* \< 0.001). No statistically significant difference in BCG vaccination was found between pulmonary and extra-pulmonary TB cases (*p* = 0.118).

Among 554 children with active TB, 481 (86.8%) patients had pulmonary TB ([Table 2](#ijms-17-00960-t002){ref-type="table"}).

In 49 children, the disease also involved other sites besides the lungs. Extra-pulmonary TB was diagnosed in 122 children; of those, 41.8% children had lymphonodal TB, 18% central nervous system (CNS) TB (meningitis in 20 cases and two intracranial tuberculoma), 19.7% bone TB, and 28.7% had other sites involved (*i.e.*, abdominal, cardiac, ocular or disseminated TB). The distribution of TB localization by to age groups is reported in [Table 3](#ijms-17-00960-t003){ref-type="table"}.

CNS TB resulted as being significantly more frequent in children under age four (*p* \< 0.009). In contrast, lymphonodal TB was more frequent in older children (*p* \< 0.003). Two children died from cardio-pulmonary complications.

2.3. Diagnosis {#sec2dot3-ijms-17-00960}
--------------

In the active TB group, 396 children were symptomatic at presentation (396/554, 71.5%) ([Table 2](#ijms-17-00960-t002){ref-type="table"}). Within the pulmonary TB group, the more common signs/symptoms were cough (52/181, 28.7%), fever (65/181, 35.9%) and weight loss (18/181, 9.9%). Hemoptysis was reported in five cases (5/181, 2.7%). The more frequent clinical manifestations regarding CNS TB were fever (16/22, 72.7%) and signs/symptoms of CNS involvement (seizures, strabismus, diplopia, and headache) (11/22, 50%).

Overall, TST was performed in all the children enrolled in the study. Within the active TB group, TST was negative in 14.8% children, whereas IGRA was negative in 8.3% of the cases and indeterminate in eight patients ([Table 4](#ijms-17-00960-t004){ref-type="table"}).

Sensitivity of TST and QFT-G-IT in the diagnosis of active TB was 85.2% (95% CI: 81.9--88) and 91.5% (95% CI: 88.4--93.9), respectively. Specificity was 97.3% (95% CI: 93.4--99.2) and 98% (95% CI: 94.2--99.5), respectively.

Imaging was performed using chest X-rays in 477 active TB cases (477/554; 86.1%) and chest computer tomography (CT) in 309 cases (309/554, 55.8%), of whom about half of the cases (148/309, 47.9%) with contrast. Other diagnostic imaging was performed using lymphonodal or abdominal ultrasound in 16 children (16/554, 2.9%) and magnetic resonance imaging in 21 cases (21/554, 3.8%).

Respiratory samples were gathered from all children with pulmonary TB. Overall, respiratory samples by gastric aspirates, sputum or bronchoalveolar lavage (BAL) were collected in 451/554 (81.4%) active TB cases. Gastric aspirates were collected in 388 active TB cases (388/554, 70%), with a median age of 40 months (IQR: 16.2--105.7). In 95.6% (*n* = 371) of the cases, the culture result was known, being positive in 152 children (152/371, 40.9%). The Ziehl--Neelsen (ZN) staining was known for 377 patients (97.1%), being positive only in 56 children (56/377, 14.8%). The molecular investigation by polymerase chain reaction (PCR) was positive in one-third of the cases (94/309, 30.4%). Considering the culture as the gold standard for the diagnosis, the sensitivity and specificity of PCR in our population were 59% (95% CI: 49.6--68.4; 67/113) and 90% (95% CI: 85--94.3; 160/177), respectively. The sensitivity and specificity of ZN were 31% (95% CI: 23.9--39.4; 46/147) and 97% (95% CI: 93.9--98.9; 206/212), respectively.

Sputum was performed in 55 children (55/554, 9.9%), aged 149 (IQR: 97.5--175) months.

Results for culture, ZN and PCR were available in 38 children (38/55, 69%). More than one-third of the cases had a positive culture (20/52, 38.4%), 19.2% a positive ZN stain (10/52), and 26.2% a positive PCR (11/42). Sensitivity and specificity of PCR compared to cultures were 64% (95% CI: 35.14--87.24; 9/14) and 92% (95% CI: 73.9--99; 23/25), respectively. The sensitivity and specificity of ZN were 53% (95% CI 28.9--75.5; 10/19) and 100% (95% CI: 88.4--100; 30/30), respectively.

Microbiological investigations were additionally performed on BAL (8/554, 1.44%), stool (4/554, 0.72%), tissue biopsy (22/554, 3.9%), urine (68/554, 12.3%) and other biological fluids such as pleural, synovial and cerebrospinal fluid (19/554, 3.4%). No microbiological data were available for 73 children (13.2%). Considering children with TB meningitis, data about cerebrospinal fluid were known for 13 children. ZN staining was positive in 18.2% (2/11) of the cases, PCR in 57.1% of the cases (4/7), and cultures in half of the cases (6/12).

2.4. Sequelae {#sec2dot4-ijms-17-00960}
-------------

The outcome was known in 507/554 patients (91.5%), since 47 children were lost at follow-up. Thirty-six children with active TB (7.1%) developed sequelae. Half of the patients with CNS involvement (*n* = 11, 50%) exhibited persistent neurological manifestations (epilepsy, neurocognitive impairment, blindness, deafness, hemiplegia or hemiparesis). In 81.9% of osteoarticular TB, sequelae such as deformity, scoliosis and lameness were reported.

2.5. Treatment {#sec2dot5-ijms-17-00960}
--------------

### 2.5.1. Active TB {#sec2dot5dot1-ijms-17-00960}

The treatment of active TB cases was known for 534 (96.4%) patients. The details on the drug used, including the median dosage, median length of treatment, and side effects are reported in [Table 5](#ijms-17-00960-t005){ref-type="table"}.

Overall, 210 (210/534; 39.3%) children were treated with three first-line drugs (isoniazid, rifampicin, pyrazinamide or ethambutol), whereas 216 (216/534; 40.4%) with four first-line drugs (isoniazid, rifampicin, pyrazinamide and ethambutol).

Fluoroquinolones were used in 42 children (42/534; 7.9%) and in particular the most used was moxifloxacin (31/42, 73.8%), which was given for a median length of 161 days. Injectable antitubercular drugs were administered in 48 children (48/534; 9%): streptomycin in 35 patients, amikacin in 12 patients, and kanamycin in one case. At least one oral bacteriostatic second-line antitubercular medication was used in 23 patients, cycloserine in half of the cases. Moreover, two antitubercular drugs, linezolid and clarithromycin, defined by WHO with unclear efficacy in MDR-TB treatment were used in 22 cases. Second-line drugs were frequently used in children without known resistances to anti-tubercular treatment (moxifloxacin: 19/31, 61.3%; linezolid 9/17, 52.9%; amikacin: 6/12, 50%; and cycloserine: 3/11, 27.3%). Side effects were reported in 35 patients. The most common one was the liver function impairment (hepatitis or hypertransaminasemia), reported in 54.3% of the cases (19/35).

Steroids were administered in 87 (16.3%) children, 38% of those received prednisone and 40% methylprednisolone. Overall, steroids in addition to the anti-tubercular treatment were used in 14 children with central nervous system (CNS) involvement, one pleuritis, one pericarditis and three miliary TB. Steroids were also used in 63 (72.4%) patients with pulmonary TB.

Regarding TB of the CNS, the treatment choice was known for 91% cases. In nine children, four first-line antitubercular drugs were used. An aminoglycoside was added to the standard treatment in five patients, in two patients a fluoroquinolone was used and cycloserine in two others.

### 2.5.2. Drug Resistant TB {#sec2dot5dot2-ijms-17-00960}

Thirty-nine (7%) children were infected with drug-resistant strains of *Mycobacterium tuberculosis*. Ten of them (25.9%) had MDR-TB and one (2.6%) had XDR-TB. In eight patients, the source case was known to have drug resistant TB. Thirty (76.9%) cases had pulmonary TB and the median age was 38 months. In our population, 15.4% of children with drug-resistant TB were Italian, whereas the country of origin was Eastern Europe in eight children, South America in eight, Africa in seven and Asia in 10 cases. Resistances per single drug are shown in [Figure 1](#ijms-17-00960-f001){ref-type="fig"}.

Six MDR-TB cases (60%) were treated with at least four second-line medications including an injective drug.

### 2.5.3. Latent TB {#sec2dot5dot3-ijms-17-00960}

Overall, the treatment of latent TB was known for 484 children (81.5%). Isoniazid alone was used in half of the cases (*n* = 264, 54.5%), with a median length of treatment of 190 days and a median daily dose of 10.1 mg/kg. In 220 children (45.5%), a combination of isoniazid and rifampicin was used with a median length treatment of 97 days. Side effects were lower in children treated with an isoniazid and rifampicin combination compared to isoniazid monotherapy (1/220, 0.45% *vs.* 5/264, 1.9%); however, this result was not statistically significant (*p* = 0.3).

3. Discussion {#sec3-ijms-17-00960}
=============

A picture of the burden of TB and pediatricians' approach in a European country with low-TB incidence is reported in this retrospective study from the Italian Register of Pediatric Tuberculosis. Our Italian Register collects data on active and latent TB cases, TB contact and adopted/immigrated children screened for TB. Previous regional data were available from different local institutions \[[@B4-ijms-17-00960],[@B5-ijms-17-00960],[@B6-ijms-17-00960],[@B7-ijms-17-00960]\]. Data from 31 Tuscan hospitals (by International Classification of Diseases-9 (ICD-9) code from the whole Tuscany region) for the years 1997--2011 were reviewed showing an increased TB incidence in children \<5 years of age reaching 13.3 (95% CI: 7.8--18.9; *p* \< 0.0001) per 100,000 in 2011 compared to 2007 \[[@B6-ijms-17-00960]\]. A study limited to two pediatric centers in Rome retrospectively reviewed data of 214 children with definite or probable active TB from 1990 to 2009 \[[@B4-ijms-17-00960]\]. In this study, almost 70% of the cases occurred in children below five years of age and more than half of the cases were among immigrants \[[@B4-ijms-17-00960]\]. The epidemiology of TB in Emilia Romagna has been evaluated though a Regional TB surveillance system, including adult and childhood cases from 1996 to 2006 \[[@B7-ijms-17-00960]\]. This study underlines immigration as an important risk factor for TB in low-incidence TB areas, with a reduction of TB cases born in Italy and an increase of cases in those born abroad \[[@B7-ijms-17-00960]\]. In our study, within the active TB group, two-thirds of the cases occurred in children from a foreign country, considering immigrants as those who had at least one immigrant parent. These data overlap with the regional Italian data and national surveillance report. The definition of immigrants in TB reports is still debated, differently attributing the case origin based on the country of birth or family ethnicity \[[@B8-ijms-17-00960],[@B9-ijms-17-00960]\]. In our study, the group resulting to have a higher TB incidence was the group of children born in Italy from foreign parents (44.4%). Similar findings were also found in an American study where the TB rate was estimated on the basis of the birth origin of children and parents, reporting that young children who were USA-born of foreign-born parents had relatively high rates of TB (53.3%) \[[@B8-ijms-17-00960],[@B9-ijms-17-00960]\]. These findings could be mainly interpreted as the result of unvaccinated children exposed to adults with a high TB-risk, often living in poor conditions, or travelling to high incidence countries. Therefore, recent literature suggests that high-risk children should be vaccinated with BCG, as is already done in some European countries (*i.e.*, United Kingdom, France, and Scandinavian countries) \[[@B10-ijms-17-00960],[@B11-ijms-17-00960],[@B12-ijms-17-00960],[@B13-ijms-17-00960],[@B14-ijms-17-00960]\]. In our study, the protective role of the BCG vaccination was not performed by a multivariate analysis because there was a high proportion of missing data on the BCG vaccination. Similarly, the finding of a higher percentage of BCG vaccinated children in the extra-pulmonary TB group (16.5% *vs.* 9.8%, *p* = 0.118), which is in contrast with the current evidence of protection of TB meningitis in children vaccinated with BCG, is probably due to the lack of data regarding BCG vaccinations in a high proportion of children. We also found that about one-third of active TB occurred in Italian children. This is an important finding for pediatricians, since in these cases TB is often diagnosed with a delay because of the lack of epidemiological suspicion.

Of note, approximately one-third of active TB was asymptomatic at presentation as it often occurs as the result of screening investigations among TB contacts.

The main problem in diagnosing childhood TB is related to its paucibacillary nature \[[@B8-ijms-17-00960]\]. In our study the sensitivity and specificity of microbiological tests were sub-optimal, in line with literature findings \[[@B15-ijms-17-00960],[@B16-ijms-17-00960],[@B17-ijms-17-00960],[@B18-ijms-17-00960]\]. TST and QFT-G-IT showed quite good sensitivity and specificity and a very low rate of indeterminate results similarly to what was already found in a multicenter study in Italy on a selected young subgroup of children from most Italian centers also present in the current Register \[[@B19-ijms-17-00960]\]. Therefore, even if our multicenter study was not specifically designed to investigate the performance of IGRAs, we can conclude that the combination of these tests become of a very large use in our setting. In fact, guidelines recommend that combinations of the available tests (immunological, radiological and microbiological) be performed in children in order to increase the diagnostic rate \[[@B20-ijms-17-00960],[@B21-ijms-17-00960],[@B22-ijms-17-00960],[@B23-ijms-17-00960]\].

The institution and development of a national Register responds to the need of monitoring childhood TB, considering that it is a potential pool for disease in adulthood and represents itself as a sentinel of disease in adult source cases. The inclusion of latent TB cases in our Register is pivotal considering that latent TB notification is not mandatory and that there is a high risk of progression in children, which is estimated to be up to 40%--50% below two years of age \[[@B23-ijms-17-00960]\]. Therefore, in our study the median age of children with active TB resulted significantly lower than latent TB (*p* \< 0.0001), confirming that the rate of progression is inversely related to age \[[@B24-ijms-17-00960]\]. The treatment of latent TB in half of the cases in our study (*n* = 220) was done with a combination of isoniazid and rifampicin for three months, with low side effects. Currently, this combination is considered safe, with a higher completion rate, and as effective as six or nine months of isoniazid monotherapy \[[@B25-ijms-17-00960]\].

Data on drug-resistant childhood TB in Italy are limited to case series \[[@B26-ijms-17-00960],[@B27-ijms-17-00960],[@B28-ijms-17-00960],[@B29-ijms-17-00960],[@B30-ijms-17-00960]\] and related to adult rates \[[@B3-ijms-17-00960]\]. In our study, the multidrug resistant TB rate was 7%, in line with the European data \[[@B3-ijms-17-00960]\]. MDR-TB was in 25.9% of cases, whereas XDR-TB was in one case. Considering their risk factors for drug resistant TB (8/39, 20.5%), a contact with a MDR-TB source case was known in eight children and in about 85% of the cases the country of origin was with a high prevalence of resistant TB strains. It is important to remember that in children it is often difficult to grow mycobacterium, therefore, the data regarding drug sensitivities underestimate the real entity of the problem. Thus, it is mandatory to obtain information on the drug sensitivities of the index case \[[@B31-ijms-17-00960]\].

Second-line drugs were used in 87 children with active TB (87/534; 16.3%). This proportion is higher than expected considering that drug resistant strains were only identified in 39 children. For example, at least one injectable anti-TB drug was used in five patients for the treatment of CNS TB, whereas a fluoroquinolone was used in two cases and cycloserine in two other cases. It can be hypothesized that second-line drugs were added to standard treatment in children with a complicated disease. However, the type of data available does not consent to clearly establish this correlation in our study. Despite the lack of standardized protocols for the therapy of drug-resistant TB in childhood, the treatment regimens are often empiric and based on a drug susceptibility pattern and disease severity, and the drugs used for children are often off-label and lack pediatric formulation \[[@B32-ijms-17-00960],[@B33-ijms-17-00960]\].

Our study has several limits. Firstly, data do not result from a surveillance system, differently from other European studies carried out in Switzerland, England, and Poland, which are, however, limited to active TB, which is mandatory reported \[[@B34-ijms-17-00960],[@B35-ijms-17-00960],[@B36-ijms-17-00960]\].

A second limitation is the high proportion of missing data, including follow-up data. However, this limitation is unfortunately common in all large retrospective multicenter studies. The retrospective monitoring is itself a limitation due to the lack of incidence data.

Improving the surveillance of childhood TB is important for healthcare workers and pediatricians. On a public health level, the understanding of the burden of the disease in the pediatric population can guide policy decisions and define priorities. Moreover, better knowledge of the distinctive aspects of childhood TB can improve the daily care of affected children. Since in our study more than 45% of active TB cases occurred before four years of age with a significantly higher proportion of CNS TB in this age group, future efforts should concentrate on the implementation of diagnostic tools and active surveillance, perhaps also extending the notification of latent TB in younger children.

4. Methods {#sec4-ijms-17-00960}
==========

A multicenter study was carried out in 27 pediatric hospitals, pediatric wards, and public health centers in Italy (see [Supplementary Material](#app1-ijms-17-00960){ref-type="app"} Form). Data were collected retrospectively covering the period of time between 1 January 2010 and 31 December 2012 through a standardized form ([Supplementary Material](#app1-ijms-17-00960){ref-type="app"} Form) and shared on the Italian Society of Pediatric Infectious Diseases network. The study was approved by the Institutional Review Board at the Department of Health Sciences, University of Florence (N. 32/14, approved on 12 November 2014). The aim of this study was to obtain epidemiologic and clinical data on childhood TB by creating and implementing the Italian Register of Pediatric Tuberculosis.

4.1. Study Design and Definitions {#sec4dot1-ijms-17-00960}
---------------------------------

We retrospectively reviewed records of children (aged \<18 years) diagnosed with active and latent TB between January 2010 and December 2012. Data on recently immigrated children screened for TB following a suspect or confirmed TB contact were also included in the study. For the purpose of this study, we considered immigrant children as those born abroad or in Italy from immigrant parents.

The following data were collected: demographic characteristics (*i.e.*, name and surname initials), clinical history including the period of observation, microbiologic results, imaging, medications and outcome. These data were retrospectively and anonymously collected for clinical purposes, therefore ethical committee approval was not requested.

All results were recorded in the study database following the international standards for the protection of privacy and personal information.

A positive tuberculin skin test (TST) was defined as an induration of 5 mm or greater in children with a suspected or confirmed TB contact or in children suspected to have TB or who are receiving immunosuppressive therapy. An induration of 10 mm or greater was considered positive in children younger than age 4 or in children with likely exposure to the TB disease. TST was defined positive with an induration of 15 mm or greater in children age 4 or older without any risk factors \[[@B24-ijms-17-00960]\].

The interferon-gamma release assay (IGRA) performed was the QuantiFERON-TB Gold-in-tube (QFT-G-IT, Cellestis, Victoria, Australia). QFT-G-IT was considered positive when the concentration of the IFN-γ after stimulation with *Mycobacterium tuberculosis* antigens was ≥0.35 IU/mL. Only a small percentage of children in few centers were also tested by means of T-SPOT.TB (T-SPOT; Immunotec, Oxford, UK). Therefore, the results by this assay are not reported here. This study was not specifically designed for the purpose of evaluating the performance of QFT-G-IT and TST on TB. However, we calculated the sensitivity and specificity of TST QFT-G-IT on active TB. For this purpose, TST and IGRA were not included in the case definition.

Due to the paucibacillar nature of active TB in children, sensitivity for the diagnosis of active TB was calculated on microbiological confirmed TB, but also on probable TB, as previously in pediatric studies \[[@B37-ijms-17-00960]\]. In particular, probable TB was defined on the basis of at least three among these findings: (1) exposure to an active TB case; (2) signs/symptoms suggestive of TB; (3) radiological findings consistent with pulmonary or extra-pulmonary TB; and (4) response to an adequate anti-tubercular treatment. Specificity of QFT-G-IT in the diagnosis of active TB was calculated defining children without active TB as those who had been investigated because of signs/symptoms suspect of TB and had some risk factors for active TB, which was reasonably excluded.

Active TB was defined as the presence of at least one clinical specimen (sputum, gastric aspirate/lavage or other biologic samples) positive for *Mycobacterium tuberculosis* on culture, microscopy, or nucleic acid amplification. An active TB diagnosis was also assigned to children with radiological and clinical findings consistent with active TB and with either exposure to a known TB case or with a positive TST and/or IGRA \[[@B24-ijms-17-00960]\]. According to the country of origin, active TB cases were divided into three groups: born in Italy from Italian parents, born in Italy from foreign parents, and born abroad from foreign parents. The presence of a positive TST or an IGRA with normal physical and radiological findings was consistent with the definition of latent TB. Patients with negative TST or IGRA and no clinical and radiological signs of TB were considered uninfected. MDR-TB was defined as a TB infection or disease caused by a strain resistant to at least isoniazid and rifampicin. XDR-TB was defined as a TB infection or disease caused by a strain resistant to isoniazid, rifampicin, at least one fluoroquinolone, and one intravenous drug (amikacin, kanamycin, or capreomicin) \[[@B24-ijms-17-00960]\].

4.2. Statistical Analysis {#sec4dot2-ijms-17-00960}
-------------------------

Statistical analysis was performed using SPSS (version 22.0, SPSS Inc., Chicago, IL, USA). Metric data were tested for normal distribution. Results were expressed as mean (standard deviations (SD)) or median (interquartile ranges (IQR)) as appropriate. Unpaired *t* test and Mann--Whitney tests were used to compare variables between groups. The χ-square test or Fisher test was performed when appropriate.

Supplementary materials can be found at <http://www.mdpi.com/1422-0067/17/6/960/s1>.
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###### 

Main characteristics of children enrolled.

  Patients Characteristics                       Uninfected *n* = 3086   Latent TB ^1^ *n* = 594   Active TB *n* = 554   All *n* = 4234
  ---------------------------------------------- ----------------------- ------------------------- --------------------- -------------------
  Sex                                                                                                                    
  Male                                           1687/308 (54.7%)        329/592 (55.6%)           256/552 (46.4%)       2272/4227 (53.7%)
  Female                                         1396/3083 (45.3%)       263/592 (44.4%)           296/552 (53.6%)       1955/4227 (46.3%)
  Age (months)---Median (IQRs) ^2^               68 (34--114)            110 (65--173)             59 (20--129)          72 (35--124)
  Age distribution                                                                                                       
  ≤1 year                                        248/3072 (8.1%)         13/594 (2.2%)             83/554 (15%)          344/4219 (8.2%)
  1--4 years                                     841/3072 (27.4%)        90/594 (15.2%)            167/554 (30.2%)       1098/4219 (26%)
  4--13 years                                    574/3072 (51.2%)        301/594 (50.7%)           216/554 (39.1%)       2091/4219 (49.6%)
  ≥13 years                                      409/3072 (13.3%)        190/594 (32%)             87/554 (15.7%)        686/4219 (16.3%)
  Status                                                                                                                 
  Dead                                           0                       0                         2/554 (0.4%)          2/4234 (0.1%)
  Lost to follow-up                              42/3086 (1.4%)          45/594 (7.6%)             47/554 (8.5%)         134/4234 (3.2%)
  Transferred to another center                  0                       0                         7/554 (1.3%)          7/4234 (0.2%)
  TB resolution                                  0                       549/594 (92.4%)           498/554 (89.9%)       4091/4234 (96.6%)
  Reason for investigation                                                                                               
  Adoption/immigrant screening                   1949/3086 (63.2%)       359/594 (60.4%)           31/553 (5.6%)         2339/4233 (55.3%)
  Contact with suspected/confirmed source case   976/3086 (31.6%)        222/594 (37.4%)           294/553 (53.2%)       1492/4233 (35.2%)
  Symptomatic                                    161/3086 (5.2%)         13/594 (2.2%)             227/553 (41%)         401/4233 (9.5%)
  Screening for use of biologic drugs            0                       0                         1/553 (0.2%)          1/4233 (0.1%)
  Country of origin                                                                                                      
  Asia                                           751/3086 (24.4%)        119/594 (20%)             77/554 (13.7%)        945/4234 (22.4%)
  South-central America                          493/3086 (16%)          71/594 (12%)              53/554 (9.6%)         617/4234 (14.6%)
  East Europe                                    590/3086 (19.1%)        175/594 (29.5%)           138/554 (24.9%)       903/4234 (21.3%)
  North America                                  1/3086 (0.1%)           0/594                     0                     1/4234 (0.1%)
  North Africa                                   217/3086 (7%)           64/594 (10.8%)            74/554 (13.4%)        355/4234 (8.4%)
  Sub-saharian Africa                            322/3086 (10.4%)        88/594 (14.8%)            51/554 (9.2%)         461/4234 (10.9%)
  Italy                                          692/3086 (22.4%)        70/594 (11.8%)            152/554 (27.4%)       914/4234 (21.6%)
  Unknown                                        20/3086 (0.6%)          7/594 (1.2%)              9/554 (1.6%)          36/4234 (0.9%)
  Source case                                                                                                            
  Unknown                                        2584/3086 (83.7%)       480/594 (80.8%)           321/554 (57.9%)       3385/4234 (79.9%)
  Household                                      150/3086 (4.8%)         70/594 (11.7%)            138/554 (24.9%)       358/4234 (8.4%)
  Family member not household                    111/3086 (3.5%)         27/594 (4.5%)             53/554 (9.5%)         191/4234 (4.5%)
  Other not household                            241/3086 (7.8%)         17/594 (2.8%)             29/554 (5.2%)         300/4234 (7%)
  BCG ^3^ vaccination status                                                                                             
  Unknown                                        698/3046 (22.9%)        165/594 (27.8%)           223/549 (40.6%)       1086/4189 (25.9%)
  Negative                                       1086/3046 (35.7%)       137/594 (23.1%)           264/549 (48.1%)       1487/4189 (35.5%)
  Positive                                       1262/3046 (41.4%)       292/594 (49.2%)           62/549 (11.3%)        1616/4189 (38.6%)
  Scar                                                                                                                   
  Unknown                                        682/2626 (26%)          179/523 (34.2%)           240/525 (45.7%)       1101/3674 (30%)
  Negative                                       1018/2626 (35.7%)       160/523 (30.6%)           240/525 (45.7%)       1418/3674 (38.6%)
  Positive                                       926/2626 (35.3%)        184/523 (35.2%)           45/525 (8.6%)         1155/3674 (31.4%)

^1^ TB: Tuberculosis; ^2^ IQR: Interquartile Range; ^3^ BCG: Bacillus Calmette--Guerin.
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###### 

Clinical signs/symptoms of the active tuberculosis cases.

  Clinical Signs/Symptoms \*                                     *n*
  -------------------------------------------------------------- -----
  Fever                                                          207
  Cough                                                          173
  Lymphnode involvement                                          49
  Weight loss                                                    43
  Gastrointestinal symptoms (nausea, vomiting, abdominal pain)   35
  Respiratory symptoms (chest pain, dyspnea)                     31
  Osteoarticular symptoms (lameness, arthralgia)                 31
  Central nervous system involvement                             17
  Sweating                                                       10
  General malaise                                                9
  Erythema nodosum                                               8
  Hemoptysis                                                     7
  Conjunctival hyperemia                                         2
  Anemia                                                         1
  Amenorrhea                                                     1
  Epistaxis                                                      1
  Microhematuria                                                 1

**\*** More than one sign/symptom is reported.
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###### 

Distribution of TB localization by age groups.

  TB ^1^ Localization      ≤4 Years   \%     \>4 Years   \%     *p*        AOR ^2^ (95% CI) ^3^
  ------------------------ ---------- ------ ----------- ------ ---------- ------------------------
  Pulmonary TB             205/432    47.5   227/432     52.5   0.56       0.670 (0.444--1.012)
  Lymph node TB            13/51      25.5   38/51       74.5   0.003      2.625 (1.366--5.047)
  CNS ^4^ TB               16/22      72.7   6/22        27.3   0.009      0.297 9 (0.114--0.770)
  Bone TB                  11/24      45.8   13/24       54.2   0.958      0.978 (0.430--2.223)
  Other site TB            7/35       20     28/35       80     0.002      3.549 (1.523--8.270)
  Genitourinary tract TB                     1/1                n.a. ^5^   n.a.

^1^ TB: tuberculosis; ^2^ AOR: adjusted odd ratio; ^3^ CI: confidence interval; ^4^ CNS: central nervous system; ^5^ n.a.: not applicable.
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###### 

Tuberculin skin test and QuantiFERON-TB Gold-in-tube (QFT-IT) results according to tuberculosis (TB) status.

  Diagnostic Tests                     Active TB (*n* = 554)   Latent TB (*n* = 594)
  ------------------------------------ ----------------------- -----------------------
  Tuberculin skin test                                         
  \<5 mm                               82 (14.8%)              65 (10.9%)
  ≥5 mm                                472 (85.2%)             529 (89.1%)
  QuantiFERON-TB Gold-in-tube **\***                           
  Negative                             36 (8.3%)               190 (34.3%)
  Positive                             388 (89.8%)             362 (65.4%)
  Indeterminate                        8 (1.8%)                1 (0.2%)

**\*** QFT-IT results were not available in 122/554 (22%) children with active TB and 41/594 (6.9%) with latent TB. Results are reported in the table on 432 children with active TB and 553 with latent TB for whom QFT-IT results were known.

ijms-17-00960-t005_Table 5

###### 

Active TB treatment.

  Drug             *n*   Median Dosage (mg/kg/day)   Median Length of Treatment (Days)   Side Effects (*n*)
  ---------------- ----- --------------------------- ----------------------------------- ---------------------------------------------------------------------------------------------------------------------
  Rifampicin       415   17.5                        240                                 Itch, vomit and headache (1); rash (1); hypertransaminasemia (4)
  Pyrazinamide     411   27                          95                                  Hypertransaminasemia (7); vomit and malaise (1); epigastric pain (1); hyperuricemia (5); drug induced hepatitis (1)
  Isoniazid        396   10                          242                                 Drug induced hepatitis (1); hypertransaminasemia (4)
  Ethambutol       245   17                          86                                  Vomit and malaise (1); neutropenia (1); drug induced hepatitis (1); epigastric pain (1)
  Streptomycin     35    19                          31                                  
  Moxifloxacin     31    10.3                        161                                 Tendinopathy (1); long QT syndrome (1)
  Linezolid        17    19.1                        108                                 
  Amikacin         12    16.8                        24,5                                
  Cycloserine      11    14.1                        220                                 
  Levofloxacin     7     11.6                        202                                 
  PAS ^1^          6     118                         172.5                               
  Ethionamide      6     15.4                        91.6                                
  Clarithromycin   5     15.6                        39.6                                
  Kanamicina       1     10                          142                                 
  Ciprofloxacin    4     17                          238                                 Vomit and weight loss (1)

^1^ PAS: *p*-aminosalicylic acid.
